Sugi Predict

Sugi Predict / Compounds / SCHEMBL356631

SCHEMBL356631

SCHEMBL356631

O=C([O-])c1occc(=O)c1O.O=C([O-])c1occc(=O)c1O.O=C([O-])c1occc(=O)c1O.[Ga+3]

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ MMP1 P03956 1/20 0.43
▸ MMP3 P08254 1/20 0.43
▸ MMP7 P09237 1/20 0.43
▸ MMP9 P14780 1/20 0.43
▸ MMP8 P22894 1/20 0.43
▸ MMP12 P39900 1/20 0.43
▸ MMP13 P45452 1/20 0.43
▸ APP P05067 7/20 0.36
▸ FTO Q9C0B1 2/20 0.35
▸ MAPK1 P28482 1/20 0.31
▸ MAOA P21397 1/20 0.31
▸ MAOB P27338 1/20 0.31
▸ DBH P09172 2/20 0.31
▸ CA1 P00915 1/20 0.30
▸ CA2 P00918 1/20 0.30
▸ PKLR P30613 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3796160 0.96 KDM4E (0.48) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL15287180 0.96 KDM4E (0.48) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL1109612 0.94 KDM4E (0.47) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL25332706 0.78 KDM4E (0.55) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL13947098 0.78 KDM4E (0.50) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL146966 0.76 KDM4E (0.48) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL23879799 0.73 KDM4E (0.50) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL23879802 0.73 KDM4E (0.50) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL23879785 0.73 KDM4E (0.50) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL7064051 0.68 KDM4E (0.40) KDM4EMAPK1CA1CA2PKLR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1714 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250345482-A1 3D PRINTED GALLIUM SCAFFOLD NORTHEAST OHIO MEDICAL UNIV (US) 2025-11-13 — — US claimed
WO-2024137849-A1 GALLIUM-LOADED HYDROGELS FOR BONE TREATMENT NORTHEAST OHIO MEDICAL UNIVERSITY (US) 2024-06-27 — — WO claimed
CN-117257955-B Application of ferredoxin reductase Fpr as target point of pseudomonas aeruginosa treatment drug 深圳大学 2024-03-15 — — CN claimed
CN-117257955-A Application of ferredoxin reductase Fpr as target point of pseudomonas aeruginosa treatment drug 深圳大学 2023-12-22 — — CN claimed
US-20220275403-A1 Methods And Compositions For Enhancing AAV-Mediated Homologous Recombination Using Ribonucleotide Reductase Inhibitors THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2022-09-01 — — US claimed
EP-4017988-A1 METHODS AND COMPOSITIONS FOR ENHANCING AAV-MEDIATED HOMOLOGOUS RECOMBINATION USING RIBONUCLEOTIDE REDUCTASE INHIBITORS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2022-06-29 — — EP claimed
US-11213530-B2 Gallium in the treatment of coronavirus disease BERNSTEIN LAWRENCE RICHARD (US) 2022-01-04 — — US claimed
US-20210393667-A1 TARGET FOR ANTI-CANCER THERAPY PHOREMOST LIMITED (GB) 2021-12-23 — — US claimed
WO-2021258086-A2 GALLIUM IN THE TREATENT OF CORONAVIRUS DISEASE BERNSTEIN LAWRENCE (US) 2021-12-23 — — WO claimed
US-20210275544-A1 Gallium in the treatment of coronavirus disease BERNSTEIN LAWRENCE RICHARD (US) 2021-09-09 — — US claimed
US-20070264310-A1 SOLVATING SYSTEM AND SEALANT FOR MEDICAL USE IN THE MIDDLE OR INNER EAR MEDTRONIC, INC. 2007-11-15 — — US claimed
US-20070264342-A1 SOLVATING SYSTEM AND SEALANT FOR MEDICAL USE IN THE SINUSES AND NASAL PASSAGES MEDTRONIC, INC. 2007-11-15 — — US claimed
US-20070231407-A1 Method of treating gallium-nitrate resistant tumors using gallium-containing compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-10-04 — — US claimed
WO-2007100382-A2 ORALLY ADMINISTRABLE GALLIUM COMPOSITIONS AND METHOD OF USE BERNSTEIN LAWRENCE R (US) 2007-09-07 — — WO claimed
WO-2007064691-A1 TREATMENT OF CANCER AND OTHER DISEASES NABIL HABIB LAB (LB) 2007-06-07 — — WO claimed
WO-2007053581-A2 GROWTH CONTROL OF ORAL AND SUPERFICIAL MICROORGANISMS USING GALLIUM COMPOUNDS SIDEROMICS, LLC (US) 2007-05-10 — — WO claimed
US-20070098815-A1 Orally Administrable Gallium Compositions and Methods of Use BERNSTEIN LAWRENCE R 2007-05-03 — — US claimed
US-20060018945-A1 Gallium inhibits biofilm formation UNIVERSITY OF IOWA RESEARCH FOUNDATION 2006-01-26 — — US claimed
US-20050227929-A1 Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent PHARMACIA & UPJOHN, LLC 2005-10-13 — — US claimed
WO-2005048942-A2 COMBINATION THERAPY COMPRISING A COX-2 INHIBITOR AND AN ANTINEOPLASTIC AGENT PHARMACIA CORPORATION (US) 2005-06-02 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070264342-A1 SOLVATING SYSTEM AND SEALANT FOR MEDICAL USE IN THE SINUSES AND NASAL PASSAGES MMP7, CFTR, MMP10 KDM4E 4360/4885LMNA 3008/4885MMP1 4/4885
US-20050227929-A1 Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent PTGES2, PTGS2, PTGER2 KDM4E 4113/4885LMNA 2764/4885MMP1 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.